

Hold EUR 30.00 Price EUR 25.44 Upside 17.9 %	Value Indicators: EUR SotP 16e: 29.71 NAV 16e: 23.81	Share data: Bloomberg: DBAN GR Reuters: DBANn.DE ISIN: DE000A1TNU7	Description: Investment in industrial and services companies for a limited period of time.
	Market Snapshot: EUR m Market cap: 0 No. of shares (m): 0 EV: -11 Freefloat MC: 0 Ø Trad. Vol. (30d): 607.84 th	Shareholders: Freefloat 75.0 % Rossmann Beteiligungs GmbH 19.9 % JP Morgan Asset Management 5.2 % Ricardo Portabella 5.0 % Royce 3.0 %	Risk Profile (WRe): 2015/16e Beta: 1.0 Price / Book: 1.1 x Equity Ratio: 93 %


First Glance: Final Q1 15/16 figures

DBAG released final Q1 15/16 figures which are in line with expectations.

- Full year guidance of EUR 25m on net income basis has already been reached after valuation gains following two divestments. As a consequence, guidance was updated in January.
- A reported NAV of EUR 24.41 (EUR 24.36 WRe) per share underlines the current undervaluation of the stock.

EUR m (year end 30.09.)	Q1 15/16	Q1 15/16e	Q1 14/15	yoy	FY 15/16e	FY 14/15	yoy
Net results of investment activity	32.5	31.5	12.2	166%	41.5	29.2	42%
Fee income of fund management and advisory services	4.8	4.4	5.2	-8%	17.3	19.2	-10%
Net result of fund services and investment activity	37.3	35.9	17.4	114%	58.8	48.4	21%
EBIT	30.8	30.3	12.4	149%	36.3	26.8	35%
Net income	30.8	30.0	13.3	132%	36.2	27.1	34%
EPS	2.25	2.19	0.97	132%	2.65	1.98	34%
NAV per share	24.41	24.36	23.17	5%	23.81	22.16	7%

- Net result for Q1 15/16 was reported at EUR 30.8m (EUR 30m WRe) as a result of two successful divestments. These transactions led to positive impact of EUR 10m in Q1. Furthermore, there was positive development at most of the portfolio companies which also contributed to these strong figures.
- First glance: The stock is trading close its reported NAV of EUR 24.41. In the past, the stock traded with a premium of 20-30% to its NAV. Therefore, current price levels are perceived to be a buying opportunity.
- DBAG will host a conference call at 10 a.m. CET today. Dial in: +49 69 210869 703; Code: 57381058




Rel. Performance vs SDAX:	
1 month:	0.4 %
6 months:	-0.5 %
Year to date:	0.4 %
Trailing 12 months:	-5.0 %

Company events:	
25.02.16	AGM
12.05.16	Q2
11.08.16	Q3


FY End: 31.10. in EUR m	CAGR (14/15-17/18e)	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Net result of fund services and investment activity	11.8 %	63	60	76	48	59	63	68
Net result investment activity		51	41	55	29	41	46	50
Fee income fund services		12	19	22	19	17	17	17
EBIT	18.6 %	46	34	48	27	36	40	45
EBT		47	34	48	27	37	41	45
Net income	18.1 %	44	32	48	27	36	40	45
EPS	18.1 %	3.25	2.36	3.51	1.98	2.65	2.95	3.26
DPS	0.0 %	1.20	1.20	2.00	1.00	1.00	1.00	1.00
Dividend Yield		7.2 %	6.2 %	9.5 %	3.6 %	3.9 %	3.9 %	3.8 %
NAV per share		19.46	20.32	22.16	22.16	23.81	25.76	28.02
Return on NAV		16.8 %	11.2 %	15.9 %	9.9 %	12.5 %	12.9 %	13.2 %
P / E		5.1 x	8.2 x	6.0 x	14.0 x	9.6 x	8.6 x	8.1 x
Net Debt		-111	-8	-19	-20	-11	-8	-12
ROE		17.6 %	11.9 %	16.5 %	8.9 %	11.5 %	11.9 %	12.1 %
ROCE (NOPAT)		34.7 %	15.2 %	17.3 %	9.4 %	12.0 %	12.2 %	12.4 %
Guidance:		updated 2015/16: Net income clearly above EUR 35m						

Net result fund services & investments
in EUR m




Source: Deutsche Beteiligungs AG, Warburg Research

Portfolio by industry
2014/15; in %



Source: Deutsche Beteiligungs AG, Warburg Research

Net income
in EUR m



Source: Deutsche Beteiligungs AG, Warburg Research


Company Background

- Deutsche Beteiligungs AG (DBAG) is a publicly-listed private equity firm sponsoring management buyouts (MBOs) and financing expansion capital.
- DBAG's business model of investing its own funds alongside those of co-investment funds helps to achieve broader diversification while earning management fees which cover most of DBAG's basic operating costs.

Competitive Quality


- DBAG has a tight focus on mainly direct investments in unlisted, operationally healthy German Mittelstand companies in the industrials and services sector with sales volumes of EUR 50m – 500m p.a.
- Differentiation is based on DBAG's long-standing track record. Since it was founded in 1965, DBAG has made more than 300 private equity investments.
- Investors value this experience which cannot be matched by new entrants and the very solid track record of generating a 15-year average return for shareholders of 15.2%.

Dividend per share
in EUR



Source: Deutsche Beteiligungs AG, Warburg Research

Net asset value per share
in EUR



Source: Deutsche Beteiligungs AG, Warburg Research

Valuation	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Price / Book	0.8 x	0.9 x	0.9 x	1.2 x	1.1 x	1.0 x	0.9 x
Book value per share ex intangibles	19.46	20.31	22.15	22.12	23.76	25.71	27.97
EV / Sales	2.3 x	4.3 x	3.7 x	7.4 x	5.7 x	5.4 x	5.1 x
EV / EBITDA	2.5 x	7.5 x	5.6 x	13.4 x	9.3 x	8.4 x	7.8 x
EV / EBIT	2.5 x	7.6 x	5.6 x	13.4 x	9.3 x	8.4 x	7.8 x
EV / EBIT adj.*	2.5 x	7.6 x	5.6 x	13.4 x	9.3 x	8.4 x	7.8 x
P / FCF	n.a.	n.a.	n.a.	56.2 x	93.4 x	87.0 x	77.0 x
P / E	5.1 x	8.2 x	6.0 x	14.0 x	9.6 x	8.6 x	8.1 x
P / E adj.*	5.9 x	9.2 x	6.9 x	14.0 x	9.6 x	8.6 x	8.1 x
Dividend Yield	7.2 %	6.2 %	9.5 %	3.6 %	3.9 %	3.9 %	3.8 %
Free Cash Flow Yield Potential	39.5 %	13.1 %	17.8 %	7.5 %	10.6 %	11.8 %	12.7 %

*Adjustments made for: -

Company Specific Items	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
NAV per share	19.46	20.32	22.16	22.16	23.81	25.76	28.02
Return on NAV	16.8 %	11.2 %	15.9 %	9.9 %	12.5 %	12.9 %	13.2 %
Net result investment activity	51	41	55	29	41	46	50
Fee income fund services	12	19	22	19	17	17	17
Net result of fund services and investment activity	63	60	76	48	59	63	68

Consolidated profit & loss

In EUR m	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Net result of fund services and investment activity	63	60	76	48	59	63	68
Net result investment activity	51	41	55	29	41	46	50
Fee income fund services	12	19	22	19	17	17	17
Personnel expenses	16	14	17	15	17	17	17
Other operating income	28	6	10	7	12	12	12
Other operating expenses	16	18	18	13	18	18	18
Unfrequent items	0	0	0	0	0	0	0
EBITDA	47	34	48	27	36	40	45
<i>Margin</i>	90.8 %	56.9 %	66.1 %	55.3 %	61.7 %	63.7 %	66.0 %
Depreciation of fixed assets	0	0	0	0	0	0	0
EBITA	46	34	48	27	36	40	45
Amortisation of intangible assets	0	0	0	0	0	0	0
Goodwill amortization	0	0	0	0	0	0	0
EBIT	46	34	48	27	36	40	45
<i>Margin</i>	90.0 %	56.2 %	66.1 %	55.3 %	61.7 %	63.7 %	66.0 %
EBIT adj.	46	34	48	27	36	40	45
Interest income	1	1	0	0	0	0	0
Interest expenses	1	1	0	0	0	0	0
Other financial income (loss)	0	0	0	0	0	0	0
EBT	47	34	48	27	37	41	45
<i>Margin</i>	91.5 %	56.4 %	66.4 %	55.9 %	62.2 %	64.2 %	66.4 %
Total taxes	1	0	0	0	0	0	0
Net income from continuing operations	46	33	48	27	36	40	45
Income from discontinued operations (net of tax)	0	0	0	0	0	0	0
Net income before minorities	46	33	48	27	36	40	45
Minority interest	2	1	0	0	0	0	0
Net income	44	32	48	27	36	40	45
<i>Margin</i>	86.6 %	53.9 %	65.8 %	55.8 %	61.6 %	63.6 %	65.8 %
Number of shares, average	14	14	14	14	14	14	14
EPS	3.25	2.36	3.51	1.98	2.65	2.95	3.26
EPS adj.	2.79	2.09	3.04	1.98	2.65	2.95	3.26


*Adjustments made for:

Guidance: updated 2015/16: Net income clearly above EUR 35m

Financial Ratios


	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
EBITDA / Interest expenses	64.8 x	41.0 x	307.1 x	171.7 x	232.7 x	259.3 x	286.3 x
Tax rate (EBT)	1.8 %	1.4 %	0.8 %	0.1 %	1.1 %	1.0 %	0.9 %
Dividend Payout Ratio	35.6 %	49.3 %	57.0 %	50.6 %	37.8 %	33.9 %	30.7 %

Net result fund services & investments
in EUR m



Source: Warburg Research

Performance per Share



Source: Warburg Research


Consolidated balance sheet

In EUR m	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Assets							
Goodwill and other intangible assets	0	0	0	1	1	1	1
thereof other intangible assets	0	0	0	0	0	0	0
thereof Goodwill	0	0	0	0	0	0	0
Property, plant and equipment	2	1	1	1	2	2	3
Financial assets	151	243	245	277	308	336	362
Other long-term assets	0	0	0	0	0	0	0
Fixed assets	152	244	246	279	310	339	366
Inventories	0	0	0	0	0	0	0
Accounts receivable	0	0	0	0	0	0	0
Liquid assets	111	11	28	28	19	17	21
Other short-term assets	36	43	58	20	20	20	20
Current assets	147	54	86	49	40	37	41
Total Assets	299	299	333	327	350	376	407
Liabilities and shareholders' equity							
Subscribed capital	49	49	49	49	49	49	49
Capital reserve	141	141	141	141	141	141	141
Retained earnings	45	2	-5	-4	18	45	76
Other equity components	31	86	118	117	117	117	117
Shareholders' equity	266	278	303	303	326	352	383
Minority interest	12	0	0	0	0	0	0
Total equity	278	278	303	303	326	352	383
Provisions	18	17	29	23	23	23	23
thereof provisions for pensions and similar obligations	0	3	9	9	9	9	9
Financial liabilities (total)	0	0	0	0	0	0	0
thereof short-term financial liabilities	0	0	0	0	0	0	0
Accounts payable	0	0	0	0	0	0	0
Other liabilities	3	4	1	1	1	1	1
Liabilities	21	21	30	24	24	24	24
Total liabilities and shareholders' equity	299	299	333	327	350	376	407

Financial Ratios


	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Efficiency of Capital Employment							
ROA	29.2 %	13.2 %	19.5 %	9.7 %	11.7 %	11.9 %	12.2 %
Return on Capital							
NAV per share	19.46	20.32	22.16	22.16	23.81	25.76	28.02
Return on NAV	16.8 %	11.2 %	15.9 %	9.9 %	12.5 %	12.9 %	13.2 %
ROCE (NOPAT)	34.7 %	15.2 %	17.3 %	9.4 %	12.0 %	12.2 %	12.4 %
ROE	17.6 %	11.9 %	16.5 %	8.9 %	11.5 %	11.9 %	12.1 %
Adj. ROE	15.1 %	10.5 %	14.3 %	8.9 %	11.5 %	11.9 %	12.1 %
Balance sheet quality							
Net Debt	-111	-8	-19	-20	-11	-8	-12
Net Financial Debt	-111	-11	-28	-28	-19	-17	-21
Net Gearing	-39.8 %	-2.9 %	-6.3 %	-6.4 %	-3.3 %	-2.4 %	-3.2 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	19.5	20.3	22.2	22.2	23.8	25.8	28.0
Book value per share ex intangibles	19.5	20.3	22.1	22.1	23.8	25.7	28.0

Return on NAV Development




Source: Warburg Research

NAV per share Development in EUR m



Source: Warburg Research

Dividend per Share in EUR



Source: Warburg Research

Consolidated cash flow statement

In EUR m	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Net income	44	32	48	27	36	40	45
Depreciation of fixed assets	0	0	0	0	0	0	0
Amortisation of goodwill	0	0	0	0	0	0	0
Amortisation of intangible assets	0	0	0	0	0	0	0
Increase/decrease in long-term provisions	0	0	0	-1	0	0	0
Other non-cash income and expenses	-54	-45	-48	-19	-32	-36	-39
Cash Flow	-10	-12	0	7	4	4	5
Increase / decrease in inventory	0	0	0	0	0	0	0
Increase / decrease in accounts receivable	0	0	0	0	0	0	0
Increase / decrease in accounts payable	0	0	0	0	0	0	0
Increase / decrease in other working capital positions	0	0	0	0	0	0	0
Increase / decrease in working capital (total)	0	0	0	0	0	0	0
Net cash provided by operating activities	-10	-12	0	7	4	4	5
Investments in intangible assets	0	0	0	0	0	0	0
Investments in property, plant and equipment	-1	-1	-1	-1	-1	-1	-1
Payments for acquisitions	0	0	0	0	0	0	0
Financial investments	22	47	116	93	50	50	50
Income from asset disposals	33	67	150	114	51	57	63
Net cash provided by investing activities	11	20	33	20	1	7	13
Change in financial liabilities	0	0	0	0	0	0	0
Dividends paid	-11	-16	-16	-27	-14	-14	-14
Purchase of own shares	0	0	0	0	0	0	0
Capital measures	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0
Net cash provided by financing activities	-11	-16	-16	-27	-14	-14	-14
Change in liquid funds	-10	-8	17	0	-9	-2	4
Effects of exchange-rate changes on cash	0	0	0	0	0	0	0
Cash and cash equivalent at end of period	23	14	28	28	19	17	21

Financial Ratios

	2011/12	2012/13	2013/14	2014/15	2015/16e	2016/17e	2017/18e
Cash Flow							
FCF	-10	-12	-1	6	4	4	5
Interest Received / Avg. Cash	1.1 %	1.6 %	1.8 %	1.6 %	1.9 %	2.5 %	2.4 %
Interest Paid / Avg. Debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the financial analysis.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the financial analysis, in a market based on the provision of buy or sell contracts
- 4- Warburg Research, or an affiliated company, were in the last twelve months bound by a service agreement with the issuers, who are themselves or their financial instruments are, subject of the financial analysis, in connection with **investment banking business** for which a service or a promise of a service emanated.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the financial analysis** with the analysed company.
- 6- Companies affiliated with Warburg Research **regularly trade** financial instruments of the analysed company or derivatives of these.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Deutsche Beteiligungs AG	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A1TNUT7.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	119	63
Hold	62	33
Sell	4	2
Rating suspended	4	2
Total	189	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment banking services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	24	77
Hold	5	16
Sell	1	3
Rating suspended	1	3
Total	31	100

PRICE AND RATING HISTORY DEUTSCHE BETEILIGUNGS AG AS OF 11.02.2016



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.

EQUITIES

Roland Rapelius +49 40 3282-2673
Head of Equities rrapelius@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Lucas Boventer +49 40 309537-290
Renewables, Internet, Media lboventer@warburg-research.com

Christian Cohrs +49 40 309537-175
Engineering, Logistics ccohrs@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Harald Hof +49 40 309537-125
Medtech hhof@warburg-research.com

Ulrich Huwald +49 40 309537-255
Health Care, Pharma uhuwald@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Eggert Kuls +49 40 309537-256
Engineering ekuls@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Malte Räther +49 40 309537-185
Telco, Internet, Media mraether@warburg-research.com

Jochen Reichert +49 40 309537-130
Telco, Internet, Media jreichert@warburg-research.com

J. Moritz Rieser +49 40 309537-260
Real Estate mrieser@warburg-research.com

Arash Roshan Zamir +49 40 309537-155
Cap. Goods, Renewables aroshanzamir@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Björn Voss +49 40 309537-254
Steel, Car Suppliers bvoss@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Holger Nass +49 40 3282-2669
Head of Equity Sales, USA hnass@mmwarburg.com

Klaus Schilling +49 40 3282-2664
Dep. Head of Equity Sales, GER kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lyubka Bogdanova +49 69 5050-7411
United Kingdom, Australia lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Paul Dontenwill +49 40 3282-2666
USA pdontenwill@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Marie-Therese Grübner +49 40 3282-2630
France, Switzerland mgruebner@mmwarburg.com

Michael Kriszun +49 40 3282-2695
United Kingdom mkriszun@mmwarburg.com

Marc Niemann +49 40 3282-2660
Germany mniemann@mmwarburg.com

Fabian Roggemann +49 40 3282-2667
USA froggemann@mmwarburg.com

Sanjay Oberoi +49 69 5050-7410
United Kingdom soberoi@mmwarburg.com

Juliane Willenbruch +49 40 3282-2694
Roadshow/Marketing jwillenbruch@mmwarburg.com

SALES TRADING

Oliver Merkel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Michael Ilgenstein +49 40 3282-2700
Sales Trading milgenstein@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Jörg Treptow +49 40 3262-2658
Sales Trading jtreptow@mmwarburg.com

Jan Walter +49 40 3262-2662
Sales Trading jwalter@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Matthias Thiel +49 40 3282-2401
Macro Research mthiel@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html
Bloomberg MMWA GO
FactSet www.factset.com

Thomson www.thomson.com
Reuters www.knowledge.reuters.com
Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com